BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended June 30, 2025 and highlighted recent developments. “During our second quarter of 2025, we continued to position the Company to advance IKT-001 toward a late-stage clinical trial in PAH,” said Mark Iwicki, Chief Executive Officer of Inhibikase. “We have now finalized our study protocol, and we expect to initiate our Phase 2b clinical study of IKT-001, our re-engineered prodrug of imatinib mesylate, in PAH in the second half of 2025.” Multiple studies including both Phase 2 and the Phase 3 IMPRES...

PEMGARDA® (pemivibart) net product revenue of $11.8 million reported for Q2 2025, representing 413% growth year-over-year Invivyd’s target of near-term profitability (1H 2025) was not met but remains possible with the upcoming respiratory virus season Announced alignment with U.S. FDA on rapid pathway to full approval (BLA) of vaccine alternative monoclonal antibody candidate VYD2311 to protect American adults and adolescents from COVID-19 Announced attractive safety profile and pharmacokinetics data for VYD2311 from our pre-pivotal first-in-human clinical trial, including 76-day observed half-life for IM route of administration, allowing for potential long-term protectionWALTHAM, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) — Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the quarter ended June 30, 2025, and provided...

FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia Evaluation of strategic alternatives BURLINGTON, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today provided business updates. FDA Discussions & Roluperidone Update The Company has had multiple interactions with the FDA following receipt of the Complete Response Letter (CRL) for its New Drug Application (NDA) in February 2024 and the FDA has confirmed the requirement for an additional confirmatory clinical trial to address the deficiencies cited in the CRL and resubmit the NDA. As in the two previous studies (C03 and C07), the required confirmatory...

— Arcadia revenues increase 11% year over year driven by 24% growth in Zola® — — Arcadia receives 2.7 million shares of stock in ABVE — — Arcadia eliminates $1M in liabilities — DALLAS, Aug. 14, 2025 (GLOBE NEWSWIRE) — Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the second quarter and first half of 2025. “We are very pleased with our performance for the second quarter of 2025,” said T.J. Schaefer, CEO of Arcadia. “While our total revenues have increased 11% compared to the second quarter of 2024, Zola® coconut water revenues have grown 24% and once again surpassed the performance of the category. Our gross margins have now exceeded 30% for ten straight quarters, while our underlying operating...

Operating cash flow grew 22% in the first half of the year Company reaffirms projected 2025 revenue of $30–35 million and 28% EBITDA margin Conference call today at 5:00 pm ET to discuss results DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) — Intermap Technologies (TSX: IMP; OTCQB: ITMSF) (“Intermap” or the “Company”), a global leader in 3D geospatial intelligence solutions, today announced its financial results for the three months ended June 30, 2025. Second quarter revenue declined year over year from $3.6 million to $3.0 million due to timing effects from Indonesia and a commercial contract. The Company generated $2.1 million of operating cash flow during the quarter compared with a use of $500 thousand in the second quarter of 2024. Operating cash flow for the six months ended June 30, 2025 of $1.4 million increased 22% over the...

SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) — Beam Global, (Nasdaq: BEEM), (the “Company”), a leading provider of innovative and sustainable infrastructure solutions for the electrification of transportation, energy security and smart city infrastructure, today announced its second quarter results for the period ended June 30, 2025. Financial Highlights12% Revenue increase from Q1 2025 to Q2 2025 60% of Revenues from Non-Government Commercial Entities YTD June 30, 2025 37% of revenues from International operations YTD June 30, 2025 Positive GAAP Gross Margin 20% for Q2 2025, a 4-percentage point increase over Q2 2024 Adjusted non-GAAP Gross Margin, net of non-cash costs 30% for Q2 2025, a 12-percentage point increase over Q2 2024 Operating costs reduced by $1.2 million in Q2 2025 compared to Q2 2024 Backlog of $7M Debt free and...

FREMONT, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — Actelis Networks, Inc. (NASDAQ: ASNS) (“Actelis” or the “Company”), a market leader in cyber-hardened, rapid deployment networking solutions for IoT and broadband applications, today reported financial results for the second quarter ended June 30, 2025. “We navigated a dynamic market environment in the second quarter, while laying the groundwork for improved growth ahead, primarily in our Federal and Military verticals where we are awaiting sizeable business that was delayed in Q2 and is expected in Q3. In addition, we have accelerated and expanded our MDU market penetration efforts in more countries and more verticals,”, said Tuvia Barlev, Chairman and CEO of Actelis. “We grew 31% in revenues sequentially vs. Q1 and we are executing multiple comprehensive...

– Well-tolerated safety profile and robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms in open label extension (OLE) 1-year trial– – Successful completion of two large randomized double-blind clinical trials, including one Phase 2 and one Phase 3 trial, a 1-year OLE trial, and clinical pharmacology studies designed to support filing of New Drug Application (NDA) – – Planned meeting with Food and Drug Administration (FDA) to discuss brilaroxazine’s path to approval for schizophrenia in Q4 2025; potential NDA submission targeted for Q2 2026 – CUPERTINO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in...

Updated data from ongoing open-label Phase 1b trial demonstrated a mean 12-month eGFR of approximately 68 mL/min/1.73 m2 post-transplant for patients on tegoprubart Company on track to report topline results from Phase 2 BESTOW trial in kidney transplantation in November 2025 Cash, cash equivalents and short-term investments of $107.6 million as of June 30, 2025 IRVINE, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today reported its second quarter 2025 operating and financial results and reviewed recent business highlights. “We are proud to enter the second half of the year with strong momentum as we have achieved all of our key milestones to date including advancing tegoprubart in kidney, islet cell (type 1 diabetes), and liver allotransplantation, as well as in xenotransplantation....

Announced CNSide® CSF assay platform launch timeline Initiated the REYOBIQ dose optimization trial for patients with leptomeningeal metastases HOUSTON, Aug. 14, 2025 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces financial results for the second quarter ended June 30, 2025, and provides an overview of recent and upcoming business highlights. “The second quarter of 2025 marked steady execution and progress on our key strategic initiatives:  clinical development of our radiotherapeutic and the advancement of our diagnostic platform technologies toward commercialization,” said Marc H. Hedrick, M.D., Plus Therapeutics President...